3:05 PM
 | 
Sep 25, 2018
 |  BC Extra  |  Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia and includes up to $114 million in an upfront and...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >